MIM 151660) caused by mutant LMNA (Cao and Hegele 2000; MIM 150330 ). The second is Berardinelli-Seip complete lipodystrophy (BSCL; MIM 260700) caused by mutant BSCL2 (Magre et al. 2001; MIM 606158) . However, there is at least one other locus for BSCL called BSCL1 (Garg et al. 1999; MIM 606166) and there might also be other loci for FPLD. Thus, it remains important to evaluate new candidate genes for lipodystrophies based on function, expression, genetic map position, and/or analogy with other phenotypes.
Nuclear receptors are transcription factors regulated by small hydrophobic hormones such as retinoic acid, thyroid hormone, and steroids (Lee et al. 1998 ). This superfamily also includes orphan nuclear receptors, which are related proteins with unspecified ligands. Small heterodimer partner 1 (SHP1), also called nuclear receptor subfamily 0, group B, member 2 (NR0B2), is a 257-amino acid protein that contains ligand-binding and dimerization domains, but lacks a DNA-binding domain (Seol et al. 1996) . Loss-offunction mutations in the SHP1 gene were reported in Japanese subjects with obesity and diabetes (Nishigori et al. 2001) . Because these traits are related to lipodystrophy, SHP1 is a potential candidate gene for lipodystrophy that is not due to mutant LMNA or BCSL2. To find disease mutations and/or single-nucleotide polymorphisms (SNPs), we sequenced SHP1 in (1) lipodystrophic patients with no sequence abnormality in known lipodystrophy genes and (2) normal controls.
Subjects and methods

Study subjects
We studied 11 subjects with typical FPLD and 4 subjects with typical BSCL. All subjects had normal sequences of both the LMNA and BSCL2 genes. All affected subjects were of European descent. Subjects with acquired or druginduced lipodystrophy were excluded. All subjects were isolated affected cases, and none came from a family that was Abstract Because mutations in human SHP1 underlie obesity and diabetes, SHP1 is a candidate gene for human lipodystrophy syndromes. To identify possible disease mutations and/or common single-nucleotide polymorphisms (SNPs), we developed primer pairs to amplify the promoter and coding region of SHP1. We used these pairs to sequence SHP1 in lipodystrophy patients who had no mutations in known lipodystrophy genes, and also in normal control subjects. We found no rare SHP1 coding sequence variants that were exclusive to patients with lipodystrophy. However, we found four polymorphisms, namely, an SNP [Ϫ394]CϾT in the promoter, a micro-deletion polymorphism [Ϫ195]delCTGA in the promoter, a missense SNP 541GϾC in exon 1 (which changed the amino acid sequence G171A), and an SNP 903CϾT in exon 2. The findings suggest that SHP1 mutations are not commonly seen in patients with lipodystrophy who had no mutations in known disease genes. However, the identification of amplification primers and polymorphisms provides tools to further investigate SHP1 for association with other phenotypes.
Introduction
Lipodystrophy is characterized by repartitioning of body fat, insulin resistance, dyslipidemia, hypertension, diabetes, and atherosclerosis (Hegele 2001) . Two forms of lipodystrophy have been characterized at the molecular level. The first is Dunnigan-type familial partial lipodystrophy (FPLD; sufficiently large to perform linkage analysis. In addition, samples from 74 clinically normal Caucasian subjects were screened to determine polymorphism allele frequencies. The study was approved by the Ethics Review Panel, University of Western Ontario.
Screening the SHP1 gene for DNA variants
To amplify coding regions and intron-exon boundaries from genomic DNA, we developed a primer set using GenBank accession numbers 17438593 and NM_021969. Primer sequences are shown in Table 1 . Amplification conditions for all exons were 94°C for 5 min, followed by 30 cycles of 30 s each at 94°C, 60°C, and 72°C, and ending with a single 10-min extension step at 72°C. The SHP1 exon 1 541GϾC SNP (which changed the amino acid sequence G171A) was genotyped by amplifying genomic DNA using the primers in Table 1 , and the amplification program described earlier. This step was followed by digestion of the 627-bp product with endonuclease AvaII. The 541G allele yielded three fragments with sizes 270, 266, and 91 bp after AvaII digestion. The 541C allele yielded two fragments with sizes 357 and 270 bp after AvaII digestion. The fragments were resolved on 2% agarose gels. The SHP1 exon 2 SNP was genotyped by amplification with the primers in Table 1 , followed by direct genomic DNA sequencing.
Genotyping of
Statistical analysis SAS version 6.12 (SAS Institute, Cary, NC, USA) was used for statistical analyses. Allele frequencies were determined from electropheretogram tracings of genomic DNA sequence, except for two SNPs assayed using restriction digestion. Chi-square analysis tested the deviation of genotype frequencies from Hardy-Weinberg predictions, with the nominal P Ͻ 0.05.
Results
Identification of polymorphisms
Genomic DNA sequencing experiments in 11 FPLD subjects with normal LMNA, 4 BSCL subjects with normal BSCL2, and 10 normal controls uncovered four polymorphisms. These were an SNP [Ϫ394]CϾT in the promoter, a microdeletion polymorphism [Ϫ195]delCTGA in the promoter, a missense SNP 541GϾC in exon 1 (which changed the amino acid sequence G171A), and an SNP 903CϾT in exon 2. These SNPs are shown in Table 2 . All SNPs were seen in affected subjects and normal controls. There were no other DNA variants detected in the samples taken from the diseased subjects.
Polymorphism frequencies in normal samples
The observed genotype frequencies of all polymorphisms did not deviate from the predictions of the Hardy-Weinberg equation. The allele frequency in 74 Caucasians for each polymorphism is shown in Table 2 .
Discussion
We report (1) primer sets to amplify coding sequences of the SHP1 gene and (2) use of these primers to sequence -TAG ACT GGA CAG TGG GCA AAG T  575  R-CAG CTC TCT GGC TCT GTG TTC T  1  F-GGA AGT GAG AGC AGA TCC CTA A  627  R-TTA GAA GCT ACC TTC CCT GGC T  2  F-AGA TCT TGG GCC AGT CTT GTC  455  R-AGC TGT TCC TAA GGA GCC AAG T F, Forward primer; R, reverse primer genomic DNA. This has resulted in (1) identification of four polymorphisms in SHP1 and (2) demonstration of no additional coding sequence variants in SHP1 in lipodystrophic subjects. Genomic DNA from these subjects will continue to be sequenced as new candidate genes are identified and prioritized for possible involvement in this phenotype. Thus, SHP1 mutations do not appear to be a common cause of lipodystrophy, although we cannot rule this possibility out because of the limited number of subjects studied herein. It is possible that others might find SHP1 mutations in lipodystrophic subjects. Despite the absence of disease association in our sample, the reagents described in this report could be helpful to screen the SHP1 gene for other studies.
